Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 3Colonic Neoplasms 2Turcot syndrome 1Recurrence 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Glioma 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 12Specimen Handling 11Cisplatin 9Radiotherapy, Intensity-Modulated 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 5Cetuximab 5Carboplatin 5Radiation 4Biopsy 4(225)Ac-DOTA-c(RGDyK) 4Taxes 3Radiotherapy 3Paclitaxel 3ipatasertib 2cemiplimab 2X-Rays 2Interviews as Topic 2Immunoglobulin G 2Docetaxel 2Disulfides 2toripalimab 1peposertib 1merphos 1durvalumab 1dehydroftorafur 1cabozantinib 1atezolizumab 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × Celecoxib × 90 days × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡